The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research DNA 52

The Pharma Data

AUGUST 3, 2021

today announced financial results for the second quarter of 2021. Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns). on a non-GAAP basis.

Biosimilars 52

Biosimilars Production Treatment FDA 52

FDA Law Blog: Biosimilars

JANUARY 11, 2024

The FIE determination released in fall 2023 involves the Reference Product AbbVie’s Humira (adalimumab) and two interchangeable biosimilars—first approved is Cyltezo (adalimumab-adbm), filed by Boehringer Ingelheim Pharmaceuticals, Inc, which was followed by Abrilada (adalimumab-afzb), filed by Pfizer.

Biosimilars 59

Biosimilars FDA Production Marketing 59

Agency IQ

AUGUST 25, 2023

New FDA guidance on interchangeable biosimilar labeling heads to White House for review The FDA has submitted a draft guidance focused on the labeling of interchangeable biosimilar products to the White House for review, which would fulfill a Biosimilar User Fee Act (BsUFA III) commitment.

Biosimilars 40

Biosimilars FDA Production Licensing 40

FDA Law Blog: Biosimilars

FEBRUARY 26, 2024

Specifically, Boehringer asked FDA to interpret “strength” for biosimilars to mean “total drug content” to the exclusion of “concentration.” mL), to be biosimilar to or interchangeable with High Concentration Humira (e.g., mL), to be biosimilar to or interchangeable with High Concentration Humira (e.g.,

FDA 59

FDA Biosimilars Production Regulations 59

The Pharma Data

MAY 4, 2021

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS. Tue, 05/04/2021 – 06:45. Tuesday, May 04, 2021 – 06:45am. <!–*/. First-Quarter 2021 Revenues of $14.6 First-Quarter 2021 Reported Diluted EPS (1) of $0.86, Adjusted Diluted EPS (2) of $0.93. Anonymous (not verified). –*/. <!–*/.q4default.bwalignc

Vaccine 40

Vaccine Production FDA Clinical Trials 40

The Pharma Data

APRIL 27, 2021

Paris, April 28, 2021. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. Sanofi has become a member of the top five companies of the 2021 Access to Medicine index.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

APRIL 30, 2021

April 30, 2021 /PRNewswire/ — AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021. “We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations,” said Richard A. .

FDA 40

FDA Production Treatment International 40

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

Each phase-in program requires the manufacturer to have had a Coverage Gap Discount Program agreement in effect in 2021, and only covers applicable drugs that have been in the market as of August 16, 2022 (i.e., of the total expenditures for all Part D drugs in 2021. had Part D expenditures on or before August 16, 2022).

Compliance 105

Compliance Drugs Pharmacy Licensing 105

FDA Law Blog: Biosimilars

NOVEMBER 1, 2023

FDA recognizes that the FD&C Act exempts licensed healthcare practitioners from certain device regulations if they manufacture devices solely for use in the course of their professional practice. For example, FDA’s regulations have exempted from certain regulatory requirements (e.g.,

Laboratories 81

Laboratories FDA Regulations Licensing 81

Agency IQ

OCTOBER 6, 2023

All products are received in one of two forms: A New Drug Application (or NDA, for pharmaceuticals) or a Biologics License Application (BLA, for biologics). There were 21 NMEs added to the FDA’s Purple Book , which provides information about all biological products licensed by the FDA. Read the AgencyIQ analysis here.

FDA 52

FDA Biosimilars Science Drugs 52

Drug Target Review

JULY 6, 2023

3 Furthermore, the act “removes a requirement to use animal studies as part of the process to obtain a license for a biological product that is biosimilar or interchangeable with another biological product.” 5002 – 117th Congress (2021-2022): FDA Modernization act 2.0 Available from: [link] Sun D, Gao W, Hu H, Zhou S.

Animal Testing 105

Animal Testing Drugs Clinical Trials Clinical Research 105

The Pharma Data

OCTOBER 18, 2021

under a cooperative development and license agreement. About Tofersen Tofersen is an antisense medicine being estimated for the implicit treatment of SOD1-ALS. Biogen certified tofersen from Ionis Pharmaceuticals,Inc. About Biogen At Biogen, our charge is clear we’re settlers in neuroscience.

Biosimilars 40

Biosimilars Protein Production Licensing Licensing 40

DrugBank

OCTOBER 4, 2024

This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams. In 2021, the Federal Trade Commission (FTC) filed a lawsuit to block Illumina's proposed $7.1

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

Agency IQ

JANUARY 19, 2024

Seventeen products were orphan drugs, fourteen were generics and eight were biosimilars. This most recent year saw 80 total opinions, compared to 92 in 2022 and 97 in 2021. The rate of negative opinions over the last three years has remained relatively stable, with three each in 2023 and 2022 and five in 2021.

Biosimilars 40

Biosimilars FDA Production Treatment 40

The Pharma Data

MAY 6, 2021

ENVI calls on the Commission to “revise the use of supplementary protection certificates based on technological and scientific advances to prevent generic and biosimilar medicines from becoming less competitive inside and outside the EU.”. . © 2021 Regulatory Affairs Professionals Society. The restriction will apply for two years. .

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Production 52

FDA Law Blog: Biosimilars

SEPTEMBER 18, 2024

FDA cited February 16, 2021, as the first date on which another manufacturer could have marketed its NMN-containing dietary supplement lawfully after submitting an NDIN to the Agency on December 3, 2020. Such a response letter is generally interpreted as a no objection letter.

Production 59

Production FDA Licensing Licensing 59

FDA Law Blog: Biosimilars

AUGUST 8, 2024

Rescheduling out of schedule I would allow for the medical use of FDA-approved prescription drugs dispensed by DEA-registered, state licensed pharmacies pursuant to prescriptions issued by similarly DEA-registered, state licensed practitioners. 28, 2021).

Regulations 59

Regulations Pharmacy Licensing Licensing 59

The Pharma Data

JANUARY 24, 2021

25, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that U.S. SHANGHAI, China, Jan.

FDA 40

FDA Clinical Trials Trials Treatment 40

FDA Law Blog: Biosimilars

FEBRUARY 29, 2024

You see, Oncopeptides has has pending at the PTO since March 2021 a PTE application for U.S. 156 or case law that would support extension of the ‘929 patent that claims the product despite revocation of the biologics license application. 6,992,207 covering PEPAXTO (Docket No. FDA-2022-E-3124 ).

FDA 59

FDA Production FDA Approval Licensing 59

The Pharma Data

FEBRUARY 4, 2021

Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $1.590 Billion; Global Rinvoq Net Revenues Were $731 Million. Percent on a GAAP Basis – Provides 2021 GAAP Diluted EPS Guidance Range of $6.69 to $6.89; Provides 2021 Adjusted Diluted EPS Guidance Range of $12.32

Production 52

Production Clinical Trials International Small Molecule 52

The Pharma Data

NOVEMBER 6, 2020

With the opinions expressed at the Advisory Committee and the data presented, the FDA will continue the review process with a decision on whether to approve the aducanumab Biologics License Application by March 7, 2021. . Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

Disease 40

Disease FDA Clinical Trials Licensing 40

The Pharma Data

JULY 27, 2021

” In June 2021, AbbVie Inc. The acquisition is subject to customary closing conditions, including applicable regulatory approvals and is expected to close in the second half of 2021. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. anti-HBV/CD3).

Production 52

Production Clinical Trials Government Disease 52

The Pharma Data

OCTOBER 29, 2020

Food and Drug Administration with Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of March 7, 2021. Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. Aducanumab is also under review with the U.S. About Aducanumab. Since October 2017 Biogen and Eisai Co.,

Disease 40

Disease Marketing Clinical Trials Treatment 40

The Pharma Data

DECEMBER 9, 2020

Food and Drug Administration, with a Prescription Drug User Fee Act (PDUFA) action date of March 7, 2021 and is also under review with the European Medicines Agency. Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. Since October 2017 Biogen and Eisai Co.,

Clinical Trials 40

Clinical Trials Drugs Disease Treatment 40

The Pharma Data

FEBRUARY 8, 2021

2021 financial outlook. Sanofi expects 2021 business EPS ( 1) to grow high single digit (3) at CER, barring unforeseen major adverse events. Applying average January 2021 exchange rates, the currency impact on 2021 business EPS is estimated to be between -4.5% In 2020, Dupixent ® sales reached €3,534 million, up 73.9%

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

2021 financial outlook. Sanofi expects 2021 business EPS ( 1) to grow high single digit (3) at CER, barring unforeseen major adverse events. Applying average January 2021 exchange rates, the currency impact on 2021 business EPS is estimated to be between -4.5% In 2020, Dupixent ® sales reached €3,534 million, up 73.9%

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

OCTOBER 29, 2020

Alexion plans to initiate a Phase 3 study of SOLIRIS in GBS in Japan in 2021, pending regulatory feedback. and EU for the ULTOMIRIS SC formulation and device combination in PNH and aHUS in the third quarter of 2021. Study results are expected in the first half of 2021.

Clinical Trials 40

Clinical Trials Trials Production Licensing 40

Agency IQ

JUNE 2, 2023

In 2022 and 2021, the Spring Unified Agenda was released in early/mid June. 6/27/2023 Notification FDORA, Section 3201 Within 180 days of the passage of FDORA, all biologics and biosimilars sponsors must submit a written notice to the FDA of all actively marketed products (i.e., not discontinued) and are available for sale.

FDA 40

FDA Science Regulations Production 40

FDA Law Blog: Biosimilars

DECEMBER 11, 2023

FDA’s assumption that 50% of the tests will be exempt is particularly baffling because the laboratories are ones licensed to perform high complexity tests. 12] In FY2020, 2021, and 2022, Third-Party Review 510(k)s accounted for 2.6%, 2.6%, and 2.5% 21, 2021), [link]. of 510(k) decisions, respectively. [13]

FDA 69

FDA Laboratories Regulations Production 69

FDA Law Blog: Biosimilars

JUNE 27, 2024

It also states that “[t]he pharmacist shall record any related information indicated by a licensed health care practitioner.” Id. Gulf Med Pharmacy; Decision and Order, 86 Fed. 72,694, 72,703 (Dec. at § 64B16-27.800(2).

Pharmacy 52

Pharmacy Drugs Regulations Licensing 52

The Pharma Data

SEPTEMBER 16, 2020

The Phase 2 CRC trial is expected to have a data readout in early 2021. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Amgen is currently enrolling six Phase 1b combination studies across various advanced solid tumors (CodeBreaK 101).

Clinical Trials 52

Clinical Trials Production Trials Government 52

Agency IQ

SEPTEMBER 29, 2023

Due to the presence of nitrosamines in certain drug products, FDA had required that drug manufacturers conduct an initial risk assessment of approved or marketed products, with an initial completion date of October 1, 2021, and then confirmatory testing due by October 1, 2023.

FDA 40

FDA Science Regulations Production 40

Agency IQ

SEPTEMBER 1, 2023

excluding Northern Ireland) as of January 1, 2021. This reliance procedure was implemented on January 1, 2021, for a planned two-year span, but last September, MHRA extended the effective period for the procedure to the end of 2023. from the E.U. on February 1, 2020 started a year-long transition period; The E.U. market more quickly.

International 40

International Regulations Production Marketing 40

The Pharma Data

SEPTEMBER 20, 2020

The Phase 2 CRC trial is expected to have a data readout in 2021. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Amgen is also currently enrolling six Phase 1b combination studies across various advanced solid tumors (CodeBreaK 101).

Clinical Trials 52

Clinical Trials Production Trials Government 52

Agency IQ

OCTOBER 27, 2023

and Annex 1 Conference Joel Welch December 18 RAPS RAPS Webcast: FDA Forecast: What’s Next for the FDA in 2024 AgencyIQ Speakers December 21 HL7 REMS Public Call PDUFA Dates expected in November and December PDUFA dates represent the expected date of a regulatory decision by the FDA on a New Drug Application or Biologics License Application.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

DECEMBER 21, 2020

. “The recent results from our NAVIGATOR trial were impressive, both in terms of the overall clinical data and the reduction in exacerbation rate with tezepelumab treatment, and we continue to work with AstraZeneca on planned regulatory filings in 2021.

Trials 40

Trials Production Clinical Trials Therapies 40